FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol FGEN. Goldman Sachs, Citi and Leerink Partners acted as lead managers on the deal.
